Design and evaluation of micellar nanocarriers for 17-allyamino-17-demethoxygeldanamycin (17-AAG)

International Journal of Pharmaceutics

Volumn 392, Issue 1-2, 2010, Pages 170-177

  Chandran, Thripthy ^a   Katragadda, Usha ^a   Teng, Quincy ^b   Tan, Chalet ^a  

^a MERCER UNIVERSITY   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

17 AAG; Drug release; PEG DSPE; Polymeric micelles; TPGS

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY(POLYETHYLENE GLYCOL 2000)]; ALPHA TOCOPHEROL POLYETHYLENE GLYCOL 1000; COPOLYMER; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; HALF LIFE TIME; HUMAN; HUMAN CELL; HYDRODYNAMICS; MICELLIZATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTINEOPLASTIC AGENTS; BENZOQUINONES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; DRUG STORAGE; HUMANS; LACTAMS, MACROCYCLIC; MAGNETIC RESONANCE SPECTROSCOPY; MICELLES; NANOPARTICLES; PARTICLE SIZE; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; SOLUBILITY; VITAMIN E;

EID: 77952740852     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.03.056     Document Type: Article

References (34)

1. Dabholkar R.D., Sawant R.M., Mongayt D.A., Devarajan P.V., Torchilin V.P. Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int. J. Pharm. 2006, 315:148-157.
2. Egorin M.J., Zuhowski E.G., Rosen D.M., Sentz D.L., Covey J.M., Eiseman J.J. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice. Cancer Chemother. Pharmacol. 2001, 47:291-302.
3. Egorin M.J., Lagattuta T.F., Hamburger D.R., Covey J.M., White K.D., Musser S.M., Eiseman J.L. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother. Pharmacol. 2002, 49:7-19.
4. Erlichman C. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin. Investig. Drugs 2009, 18:861-868.
5. Gao Z., Lukyanov A.N., Singhal A., Torchilin V.P. Diacyllipid-polymer micelles as nanocarriers for poorly soluble anticancer drugs. Nano Lett. 2002, 2:979-982.
6. Gaucher G., Dufresne M.-H., Sant V.P., Kang N., Maysinger D., Leroux J.-C. Block copolymer micelles: preparation, characterization and application in drug delivery. J. Control. Release 2005, 109:169-188.
7. Glaze E.R., Lambert A.L., Smith A.C., Page J.G., Johnson W.D., McCormick D.L., Brown A.P., Levine B.S., Covey J.M., Egorin M.J., Eiseman J.L., Holleran J.L., Sausville E.A., Tomaszewski J.E. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother. Pharmacol. 2005, 56:637-647.
8. Goetz M.P., Toft D., Reid J., Ames M., Stensgard B., Safgren S., Adjei A.A., Sloan J., Atherton P., Vasile V., Salazaar S., Adjei A., Croghan G., Erlichman C. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J. Clin. Oncol. 2005, 23:1078-1087.
9. Grem J.L., Morrison G., Guo X.-D., Agnew E., Takimoto C.H., Thomas R., Szabo E., Grochow L., Grollman F., Hamilton J.M., Neckers L., Wilson R.H. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J. Clin. Oncol. 2005, 23:1885-1893.
10. Guo W., Reigan P., Siegel D., Ross D. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action. Drug Metab. Dispos. 2008, 36:2050-2057.
11. Heath E.I., Hilman D.W., Vaishampayan U., Sheng S., Sarkar F., Harperet F., Gaskins M., Pitot H.C., Tan W., Ivy S.P., Pili R., Carducci M.A., Erlichman C., Liu G. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 2008, 14:7940-7946.
12. Hollingshead M., Alley M., Burger A.M., Borgel S., Pacula-Cox C., Fiebig H.-H., Sausville E.A. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother. Pharmacol. 2005, 56:115-125.
13. Isaacs J.S., Xu W., Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3:213-217.
14. Kastantin M., Ananthanarayanan B., Karmali P., Ruoslahti E., Tirrell M. Effect of the lipid chain melting transition on the stability of DSPE-PEG(2000) micelles. Langmuir 2009, 25:7279-7286.
15. Lukyanov A.N., Gao Z., Mazzola L., Torchilin V.P. Polyethylene glycol-diacyllipid micelles demonstrate increased accumulation insubcutaneous tumors in mice. Pharm. Res. 2002, 19:1424-1429.
16. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res. 1986, 46:6387-6392.
17. Matsumura Y. Poly(amino acid) micelles nanocarriers in preclinical and clinical studies. Adv. Drug Deliv. Rev. 2008, 60:899-914.
18. Modi S., Stopeck A.T., Gordon M.S., Mendelson D., Solit D.B., Bagatell R., Ma W., Wheler J., Rosen N., Norton L., Cropp G.F., Johnson R.G., Hannah A.L., Hudis C.A. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: a phase I dose-escalation study. J. Clin. Oncol. 2007, 25:5410-5417.
19. Mu L., Elbayoumi T.A., Torchilin V.P. Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-α-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin. Int. J. Pharm. 2005, 306:142-149.
20. Musacchio T., Laquintana V., Latrofa A., Trapani G., Torchilin V.P. PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect. Mol. Pharm. 2009, 6:468-479.
21. Nishiyama N., Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Ther. 2006, 112:630-648.
22. Onyüksel H., Mohanty P.S., Rubinstein I. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer. Int. J. Pharm. 2009, 365:157-161.
23. Ramalingan S.S., Egorin M.J., Ramanathan R.K., Remick S.C., Sikorski R.P., Lagattuta T.F., Chatta G.S., Friedland D.M., Stoller R.G., Potter D.M., Ivy S.P., Belani C.P. A phase I study of 17-allyamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin. Cancer Res. 2008, 14:3456-3461.
24. Roforth M.M., Tan C. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells. Anti-Cancer Drugs 2008, 19:681-688.
25. Sain N., Krishnan B., Ormerod M.G., Rienzo A.D., Liu W.M., Kaye S.B., Workman P., Jackman A.L. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demthoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol. Cancer Ther. 2006, 5:1197-1208.
26. Shin H.-C., Alani A.W.G., Rao D.A., Rockich N.C., Kwon G.S. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drug. J. Control. Release 2009, 14:294-300.
27. Solit D.B., Ivy S.P., Kopil C., Sikorski R., Morris M.J., Slovin S.F., Kelly W.K., DeLaCruz A., Curley T., Heller G., Larson S., Schwartz L., Egorin M.J., Rosen N., Scher H.I. Phase I trial of 17-allyamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin. Cancer Res. 2007, 13:1775-1782.
28. Solit D.S., Osman I., Polsky D., Panageas K.S., Daud A., Goydos J.S., Teitcher J., Wolchok J.D., Germino F.J., Krown S.E., Coit D., Rosen N., Chapman P.B. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res. 2008, 14:8302-8307.
29. Sydor J.R., Normant E., Pien C.S., Porter J.R., Ge J., Grenier L., Pak R.H., Ali J.A., Dembski M.S., Hudak J., Patterson J., Penders C., Pink M., Read M.A., Sang J., Woodward C., Zhang Y., Grayzel D.S., Wright J., Barrett J.A., Palombella V.J., Adams J., Tong J.K. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:17408-17413.
30. Tang N., Du G., Wang N., Liu C., Hang H., Liang W. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J. Natl. Cancer Inst. 2007, 99:1004-1015.
31. Tse A.N., Klimstra D.S., Gonen M., Shah M., Sheikh T., Sikorski R., Carvajal R., Mui J., Tipian C., O'Reilly E., Chung K., Maki R., Lefkowitz R., Brown K., Manova-Todorova K., Wu N., Egorin M.J., Kelsen D., Schwartz G.K. A phase I dose-escalation study of irinotecan in combination with 17-allyamino-17-demethoxygeldanamycin in patients with solid tumors. Clin. Cancer Res. 2008, 14:6704-6711.
32. Weigel B.J., Blaney S.M., Reid J.M., Safgren S.L., Bagatell R., Kersey J., Neglia J.P., Ivy S.P., Ingle A.M., Whitesell L., Gilbertson R.J., Krailo M., Ames M., Adamson P.C. A phase I study of 17-allyaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a children oncology group study. Clin. Cancer Res. 2007, 13:1789-1793.
33. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5:761-772.
34. Xiong M.P., Yáñez J.A., Kwon G.S., Davies N.M., Forrest M.L. A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats. J. Pharm. Sci. 2009, 98:1577-1586.